02:53 AM EDT, 10/28/2026 (MT Newswires) -- Biotechnology company Oncoinvent (ONCIN.OL) appointed Zuzana Trnková as its new chief medical officer, succeeding Kari Myren, effective Nov. 4. Trnková most recently served as chief medical officer at clinical-stage biotechnology company Highlight Therapeutics, according to a Wednesday release.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.